Short Interest in Oculis Holding AG (NASDAQ:OCS) Increases By 127.3%

Oculis Holding AG (NASDAQ:OCS) saw a large growth in short interest during the month of February. As of February 15th, there was short interest totalling 29,100 shares, a growth of 127.3% from the January 31st total of 12,800 shares. Based on an average trading volume of 70,000 shares, the short-interest ratio is currently 0.4 days. Currently, 0.1% of the shares of the company are sold short.

Oculis Price Performance

NASDAQ:OCS opened at $19.58 on Monday. Oculis has a 52 week low of $10.55 and a 52 week high of $23.08. The company has a quick ratio of 4.02, a current ratio of 4.02 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $793.07 million, a PE ratio of -10.15 and a beta of -0.24. The stock’s 50-day moving average price is $20.58 and its 200-day moving average price is $16.53.

Analysts Set New Price Targets

A number of equities analysts have weighed in on OCS shares. Chardan Capital reiterated a “buy” rating and set a $28.00 price objective on shares of Oculis in a research note on Tuesday, January 7th. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Oculis in a research report on Monday, January 6th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $28.80.

Institutional Investors Weigh In On Oculis

Several institutional investors have recently bought and sold shares of OCS. Bellevue Group AG acquired a new stake in Oculis in the 4th quarter worth about $170,000. XTX Topco Ltd acquired a new stake in Oculis in the 4th quarter worth about $225,000. Geode Capital Management LLC boosted its holdings in Oculis by 12.0% in the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company’s stock worth $284,000 after buying an additional 1,800 shares during the last quarter. Citadel Advisors LLC acquired a new stake in Oculis in the 4th quarter worth about $389,000. Finally, Bank of America Corp DE boosted its holdings in Oculis by 58.2% in the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company’s stock worth $493,000 after buying an additional 10,667 shares during the last quarter. 22.30% of the stock is currently owned by institutional investors and hedge funds.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.